47 search results for: Bullous Pemphigoid
Etiology and Diagnosis of Bullous Pemphigoid
Professor Joost Meijer discusses the complex etiology and diagnosis of BP
Pathophysiology of Blister Formation in Bullous Pemphigoid
Professor Enno Schmidt discusses the pathophysiology of BP, focusing on the role of type 2 inflammation and blister formation
Importance of Early Diagnosis in Bullous Pemphigoid
Join Dr. Werth as she outlines how early diagnosis and treatment are critical to minimize risk and improve long term outcomes in patients with BP.
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP
Risk of Mortality and Infections in Bullous Pemphigoid
Dr. Victoria Werth walks through the serious comorbidity risks associated with BP diagnosis
Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid
Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms
Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies
In this ADVENT symposium at the 2024 EADV meeting, Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP.
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Enno Schmidt highlights the role of type 2 cytokines involved in the dysregulated Type 2 immune responses that contribute to inflammation and subsequent itch in bullous pemphigoid.
ADVENT at EADV 2024
Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.
New Horizons: The Emergence of Targeted Therapies
In this ADVENT symposium at the 2024 EADV meeting, Professor Dedee Murrell reviews the current treatment guidelines for bullous pemphigoid (BP) and the emergence of targeted therapies including a highlight of the LIBERTY-BP ADEPT interim results.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
